Vitamin d, phosphate, and vasculotoxicity

Canadian Journal of Physiology and Pharmacology

Volumn 93, Issue 12, 2015, Pages 1077-1082

  Brown, Ronald B ^a   Haq, Afrozul ^b   Stanford, Charles F ^b   Razzaque, Mohammed S ^b,c  

^a KANSAS STATE UNIVERSITY   (United States)

^b VPS Healthcare Group   (United Arab Emirates)

^c FORSYTH INSTITUTE   (United States)

Author keywords

Blood vessels; Calcification; Phosphate

Indexed keywords

CALCIUM; FIBROBLAST GROWTH FACTOR 23; PHOSPHATE; VITAMIN D;

BLOOD VESSEL CALCIFICATION; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; HUMAN; NONHUMAN; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRIORITY JOURNAL; REVIEW; VASCULAR SMOOTH MUSCLE CELL; VITAMIN D DEFICIENCY; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION; ANIMAL; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; METABOLISM; VASCULAR DISEASE;

ANIMALS; CALCIUM; HUMANS; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC; VASCULAR DISEASES; VITAMIN D;

EID: 84947596813     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2015-0083     Document Type: Review

References (98)

1. Annweiler, C., Schott, A.M., Berrut, G., Chauvire, V., Le Gall, D., Inzitari, M., et al. 2010.Vitamin D and ageing: neurological issues. Neuropsychobiology, 62(3): 139–150. doi:10.1159/000318570. PMID:20628264.
2. Askar, A.M. 2015. Hyperphosphatemia. The hidden killer in chronic kidney disease. Saudi Med. J. 36(1): 13–19. doi:10.15537/smj.2015.1.9843. PMID:25629999.
3. Autier, P., Boniol, M., Pizot, C., and Mullie, P. 2014. Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol. 2(1): 76–89. doi:10.1016/S2213-8587(13)70165-7. PMID:24622671.
4. Baeke, F., Gysemans, C., Korf, H., and Mathieu, C. 2010.Vitamin D insufficiency: implications for the immune system. Pediatr. Nephrol. 25(9): 1597–1606. doi: 10.1007/s00467-010-1452-y. PMID:20180136.
5. Bai, X., Miao, D., Li, J., Goltzman, D., and Karaplis, A.C. 2004. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology, 145(11): 5269–5279. doi:10.1210/en.2004-0233. PMID:15284207.
6. Bergwitz, C., and Juppner, H. 2010.Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu. Rev. Med. 61: 91–104. doi:10.1146/annurev.med.051308.111339. PMID:20059333.
7. Berndt, T., and Kumar, R. 2007. Phosphatonins and the regulation of phosphate homeostasis. Annu. Rev. Physiol. 69: 341–359. doi:10.1146/annurev.physiol.69.040705.141729. PMID:17002592.
8. Binderup, L., Latini, S., Binderup, E., Bretting, C., Calverley, M., and Hansen, K. 1991. 20-epi-vitamin D3 analogues: a novel class of potent regulators of cell growth and immune responses. Biochem. Pharmacol. 42(8): 1569–1575. doi: 10.1016/0006-2952(91)90426-6. PMID:1656990.
9. Bolland, M.J., Barber, P.A., Doughty, R.N., Mason, B., Horne, A., Ames, R., et al. 2008. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ, 336(7638): 262–266. doi:10.1136/bmj.39440.525752.BE. PMID:18198394.
10. Bolland, M.J., Grey, A., Avenell, A., Gamble, G.D., and Reid, I.R. 2011. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and metaanalysis. BMJ, 342: d2040. doi:10.1136/bmj.d2040. PMID:21505219.
11. Bolland, M.J., Grey, A., Gamble, G.D., and Reid, I.R. 2014. The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: authors’ reply. Lancet Diabetes Endocrinol. 2(5): 364–365. doi:10.1016/S2213-8587(14)70100-7. PMID:24795249.
12. Braun, J., Oldendorf, M., Moshage, W., Heidler, R., Zeitler, E., and Luft, F.C. 1996. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am. J. Kidney Dis. 27(3): 394–401. doi:10.1016/S0272-6386(96)90363-7. PMID:8604709.
13. Brown, R.B., and Razzaque, M.S. 2015. Dysregulation of phosphate metabolism and conditions associated with phosphate toxicity. Bonekey Rep. 4: 705. doi:10.1038/bonekey.2015.74. PMID:26131357.
14. Cofan, F., Garcia, S., Combalia, A., Campistol, J.M., Oppenheimer, F., and Ramon, R. 1999. Uremic tumoral calcinosis in patients receiving longterm hemodialysis therapy. J. Rheumatol. 26(2): 379–385. PMID:9972973.
15. Daniel, C., Radeke, H.H., Sartory, N.A., Zahn, N., Zuegel, U., Steinmeyer, A., et al. 2006. The new low calcemic vitamin D analog 22-ene-25-oxa-vitamin D prominently ameliorates T helper cell type 1-mediated colitis in mice. J. Pharmacol. Exp. Ther. 319(2): 622–631. doi:10.1124/jpet.106.107599. PMID:16914561.
16. Del Valle, E., Negri, A.L., Aguirre, C., Fradinger, E., and Zanchetta, J.R. 2007. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial. Int. 11(3): 315–321. doi:10.1111/j.1542-4758.2007.00186.x. PMID:17576296.
17. DeLuca, S., Sitara, D., Kang, K., Marsell, R., Jonsson, K., Taguchi, T., et al. 2008. Amelioration of the premature ageing-like features of Fgf-23 knockout mice by genetically restoring the systemic actions of FGF-23. J. Pathol. 216(3): 345–355. doi:10.1002/path.2409. PMID:18729070.
18. Dusso, A.S., Brown, A.J., and Slatopolsky, E. 2005. Vitamin D. Am. J. Physiol. Renal Physiol. 289(1): F8–F28. doi:10.1152/ajprenal.00336.2004. PMID:15951480.
19. El-Abbadi, M., and Giachelli, C.M. 2007. Mechanisms of vascular calcification. Adv. Chronic Kidney Dis. 14(1): 54–66. doi:10.1053/j.ackd.2006.10.007. PMID: 17200044.
20. Foley, R.N., Collins, A.J., Herzog, C.A., Ishani, A., and Kalra, P.A. 2009. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J. Am. Soc. Nephrol. 20(2): 397–404. doi:10.1681/ASN.2008020141. PMID:18987306.
21. Franco, M., Albano, L., Gaid, H., Gigante, M., Barrillon, D., and Jaeger, P. 2005. Resolution of tumoral calcinosis in a hemodialysis patient using low calcium dialysate. Joint Bone Spine, 72(1): 95–97. doi:10.1016/j.jbspin.2004.09.004. PMID:15681261.
22. Goldsmith, D.J., Covic, A., Sambrook, P.A., and Ackrill, P. 1997. Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron, 77(1): 37–43. doi:10.1159/000190244. PMID:9380236.
23. Heikinheimo, R.J., Inkovaara, J.A., Harju, E.J., Haavisto, M.V., Kaarela, R.H., Kataja, J.M., et al. 1992. Annual injection of vitamin D and fractures of aged bones. Calcif. Tissue Int. 51(2): 105–110.doi:10.1007/BF00298497. PMID: 1422948.
24. Holick, M.F. 2007. Vitamin D deficiency. N. Engl. J. Med. 357(3): 266–281. doi:10.1056/NEJMra070553. PMID:17634462.
25. Horst, R.L., Goff, J.P., and Reinhardt, T.A. 1997. Calcium and vitamin D metabolism during lactation. J. Mammary Gland Biol. Neoplasia, 2(3): 253–263. doi: 10.1023/A:1026384421273. PMID:10882309.
26. Hsia, J., Heiss, G., Ren, H., Allison, M., Dolan, N.C., Greenland, P., et al. 2007. Calcium/vitamin D supplementation and cardiovascular events. Circulation, 115(7): 846–854. doi:10.1161/CIRCULATIONAHA.106.673491. PMID:17309935.
27. Izquierdo, M.C., Perez-Gomez, M.V., Sanchez-Nino, M.D., Sanz, A.B., Ruiz-Andres, O., Poveda, J., et al. 2012. Klotho, phosphate and inflammation/ageing in chronic kidney disease. Nephrol. Dial. Transplant. 27(Suppl. 4): iv6–iv 10.doi:10.1093/ndt/gfs426. PMID:23258814.
28. Jackson, R.D., LaCroix, A.Z., Gass, M., Wallace, R.B., Robbins, J., Lewis, C.E., et al. 2006. Calcium plus vitamin D supplementation and the risk of fractures. N. Engl. J. Med. 354(7): 669–683. doi:10.1056/NEJMoa055218. PMID:16481635.
29. Jacob, A.I., Sallman, A., Santiz, Z., and Hollis, B.W. 1984. Defective photoproduction of cholecalciferol in normal and uremic humans. J. Nutr. 114(7): 1313–1319. PMID:6330321.
30. Jap, T.S., Chiu, C.Y., Niu, D.M., and Levine, M.A. 2011. Three novel mutations in the PHEX gene in Chinese subjects with hypophosphatemic rickets extends genotypic variability. Calcif. Tissue Int. 88(5): 370–377. doi:10.1007/s00223-011-9465-5. PMID:21293852.
31. Kalantar-Zadeh, K., and Kovesdy, C.P. 2009. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 4(9): 1529–1539. doi:10.2215/CJN.02140309. PMID:19661219.
32. Kandula, P., Dobre, M., Schold, J.D., Schreiber, M.J., Jr., Mehrotra, R., and Navaneethan, S.D. 2011. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin. J. Am. Soc. Nephrol. 6(1): 50–62. doi:10.2215/CJN.03940510. PMID:20876671.
33. Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., et al. 1997. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature, 390(6655): 45–51. doi:10.1038/36285. PMID:9363890.
34. Lanzer, P., Boehm, M., Sorribas, V., Thiriet, M., Janzen, J., Zeller, T., et al. 2014. Medial vascular calcification revisited: review and perspectives. Eur. Heart J. 35(23): 1515–1525. doi:10.1093/eurheartj/ehu163. PMID:24740885.
35. Lips, P. 2001. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr. Rev. 22(4): 477–501. doi:10.1210/edrv.22.4.0437. PMID:11493580.
36. Liu, S., and Quarles, L.D. 2007. How fibroblast growth factor 23 works. J. Am. Soc. Nephrol. 18(6): 1637–1647. doi:10.1681/ASN.2007010068. PMID:17494882.
37. Liu, S., Zhou, J., Tang, W., Jiang, X., Rowe, D.W., and Quarles, L.D. 2006. Pathogenic role of Fgf23 in Hyp mice. Am. J. Physiol. Endocrinol. Metab. 291(1): E38–E49. doi:10.1152/ajpendo.00008.2006. PMID:16449303.
38. London, G.M., Guerin, A.P., Marchais, S.J., Metivier, F., Pannier, B., and Adda, H. 2003. Arterial media calcification in end-stage renal disease: impact on allcause and cardiovascular mortality. Nephrol. Dial. Transplant. 18(9): 1731–1740. doi:10.1093/ndt/gfg414. PMID:12937218.
39. Lorenz-Depiereux, B., Bastepe, M., Benet-Pages, A., Amyere, M., Wagenstaller, J., Muller-Barth, U., et al. 2006. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat. Genet. 38(11): 1248–1250. doi:10.1038/ng1868. PMID: 17033625.
40. Martineau, A.R., Wilkinson, K.A., Newton, S.M., Floto, R.A., Norman, A.W., Skolimowska, K., et al. 2007. IFN-gamma- and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J. Immunol. 178(11): 7190–7198. doi:10.4049/jimmunol.178.11.7190. PMID:17513768.
41. Meema, H.E., and Oreopoulos, D.G. 1986. Morphology, progression, and regression of arterial and periarterial calcifications in patients with end-stage renal disease. Radiology, 158(3): 671–677. doi:10.1148/radiology.158.3.3945736. PMID: 3945736.
42. Melamed, M.L., Michos, E.D., Post, W., and Astor, B. 2008. 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch. Intern. Med. 168(15): 1629–1637. doi:10.1001/archinte.168.15.1629. PMID:18695076.
43. Merjanian, R., Budoff, M., Adler, S., Berman, N., and Mehrotra, R. 2003. Coronary artery, aortic wall, and valvular calcification in nondialyzed individuals with type 2 diabetes and renal disease. Kidney Int. 64(1): 263–271. doi:10.1046/j.1523-1755.2003.00068.x. PMID:12787418.
44. Mizobuchi, M., Ogata, H., Koiwa, F., Kinugasa, E., and Akizawa, T. 2009. Vitamin D and vascular calcification in chronic kidney disease. Bone, 45(Suppl. 1): S26–S29. doi:10.1016/j.bone.2009.01.011. PMID:19442619.
45. Monk, R.D., and Bushinsky, D.A. 2011. Making sense of the latest advice on vitamin D therapy. J. Am. Soc. Nephrol. 22(6): 994–998. doi:10.1681/ASN.2011030251. PMID:21617120.
46. Nabeshima, Y. 2006. Toward a better understanding of Klotho. Sci. Aging Knowledge Environ. 2006(8): pe11. doi:10.1126/sageke.2006.8.pe11. PMID:16672727.
47. Nakatani, T., Sarraj, B., Ohnishi, M., Densmore, M.J., Taguchi, T., Goetz, R., et al. 2009. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23)-mediated regulation of systemic phosphate homeostasis. FASEB J. 23(2): 433–441. doi:10.1096/fj.08-114397. PMID:18835926.
48. Nestle, M., and Nesheim, M.C. 2013. To supplement or not to supplement: the U.S. Preventive Services Task Force recommendations on calcium and vitamin D. Ann. Intern. Med. 158(9): 701–702. doi:10.7326/0003-4819-158-9-201305070-00605. PMID:23440174.
49. Ohnishi, M., and Razzaque, M.S. 2010.Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J. 24(9): 3562–3571. doi: 10.1096/fj.09-152488. PMID:20418498.
50. Ohnishi, M., and Razzaque, M.S. 2013. Osteo-renal cross-talk and phosphate metabolism by FGF23–klotho system. Contrib. Nephrol. 180: 1–13. doi:10.1159/000346774. PMID:23652546.
51. Ohnishi, M., Nakatani, T., Lanske, B., and Razzaque, M.S. 2009a. In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25-dihydroxyvitamin d levels. Circ. Cardiovasc. Genet. 2(6): 583–590. oi:10.1161/CIRCGENETICS.108.847814. PMID:20031638.
52. Ohnishi, M., Nakatani, T., Lanske, B., and Razzaque, M.S. 2009b. Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase. Kidney Int. 75(11): 1166–1172. doi:10.1038/ki.2009.24. PMID:19225558.
53. Ohnishi, M., Kato, S., Akiyoshi, J., Atfi, A., and Razzaque, M.S. 2011a. Dietary and genetic evidence for enhancing glucose metabolism and reducing obesity by inhibiting klotho functions. FASEB J. 25(6): 2031–2039. doi:10.1096/fj.10-167056. PMID:21382979.
54. Ohnishi, M., Kato, S., and Razzaque, M.S. 2011b. Genetic induction of phosphate toxicity significantly reduces the survival of hypercholesterolemic obese mice. Biochem. Biophys. Res. Commun. 415(3): 434–438. doi:10.1016/j.bbrc.2011. PMID:22037453.
55. Parfitt, A.M. 1969. Soft-tissue calcification in uremia. Arch. Intern. Med. 124(5): 544–556. doi:10.1001/archinte.1969.00300210026004, 10.1001/archinte.124.5.544. PMID:4899444.
56. Pilz, S., Iodice, S., Zittermann, A., Grant, W.B., and Gandini, S. 2011. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am. J. Kidney Dis. 58(3): 374–382. doi:10.1053/j.ajkd.2011.03.020. PMID:21636193.
57. Quarles, L.D., Murphy, G., Econs, M.J., Martinez, S., Lobaugh, B., and Lyles, K.W. 1991. Uremic tumoral calcinosis: preliminary observations suggesting an association with aberrant vitamin D homeostasis. Am. J. Kidney Dis. 18(6): 706–710.doi:10.1016/S0272-6386(12)80614-7. PMID:1962658.
58. Razzaque, M.S. 2007. Can fibroblast growth factor 23 fine-tune therapies for diseases of abnormal mineral ion metabolism? Nat. Clin. Pract. Endocrinol. Metab. 3(12): 788–789. doi:10.1038/ncpendmet0667. PMID:17925800.
59. Razzaque, M.S. 2009. FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player? Am. J. Physiol. Renal Physiol. 296(3): F470–F476. doi:10.1152/ajprenal.90538.2008. PMID:19019915.
60. Razzaque, M.S. 2011a. The dualistic role of vitamin D in vascular calcifications. Kidney Int. 79(7): 708–714. doi:10.1038/ki.2010.432. PMID:20962746.
61. Razzaque, M.S. 2011b. Osteo-renal regulation of systemic phosphate metabolism. IUBMB Life, 63(4): 240–247. doi:10.1002/iub.437. PMID:21438115.
62. Razzaque, M.S. 2011c. Phosphate toxicity: new insights into an old problem. Clin. Sci. (Lond.), 120(3): 91–97. doi:10.1042/CS20100377. PMID:20958267.
63. Razzaque, M.S. 2013. Phosphate toxicity and vascular mineralization. Contrib. Nephrol. 180: 74–85. doi:10.1159/000346784. PMID:23652551.
64. Razzaque, M.S. 2014. Bone-kidney axis in systemic phosphate turnover. Arch. Biochem. Biophys. 561: 154–158. doi:10.1016/j.abb.2014.06.031. PMID:24997362.
65. Razzaque, M.S., and Lanske, B. 2006. Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice. Trends Mol. Med. 12(7): 298–305. doi:10.1016/j.molmed.2006.05.002. PMID:16731043.
66. Razzaque, M.S., and Lanske, B. 2007. The emerging role of the fibroblast growth factor-23–klotho axis in renal regulation of phosphate homeostasis. J. Endocrinol. 194(1): 1–10.doi:10.1677/JOE-07-0095. PMID:17592015.
67. Razzaque, M.S., Sitara, D., Taguchi, T., St-Arnaud, R., and Lanske, B. 2006. Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J. 20(6): 720–722. doi:10.1096/fj.05-5432fje. PMID:16436465.
68. Rebsamen, M.C., Sun, J., Norman, A.W., and Liao, J.K. 2002. 1alpha,25- dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ. Res. 91(1): 17–24. doi:10.1161/01.RES.0000025269.60668.0F. PMID:12114317.
69. Reid, I.R., and Bolland, M.J. 2008. Calcium supplementation and vascular disease. Climacteric, 11(4): 280–286. doi:10.1080/13697130802229639. PMID: 18645693.
70. Reid, I.R., Bolland, M.J., and Grey, A. 2008. Effect of calcium supplementation on hip fractures. Osteoporos. Int. 19(8): 1119–1123. doi:10.1007/s00198-008-0563-9. PMID:18286218.
71. Reid, I.R., Bolland, M.J., Avenell, A., and Grey, A. 2011. Cardiovascular effects of calcium supplementation. Osteoporos. Int. 22(6): 1649–1658. doi:10.1007/s00198-011-1599-9. PMID:21409434.
72. Rickers, H., Christiansen, C., Christensen, P., Christensen, M., and Rodbro, P. 1985. Serum concentrations of vitamin D metabolites in different degrees of impaired renal function. Estimation of renal and extrarenal secretion rate of 24,25-dihydroxyvitamin D. Nephron, 39(3): 267–271. PMID:3871920.
73. Sato, K.A., Gray, R.W., and Lemann, J., Jr.. 1982. Urinary excretion of 25- hydroxyvitamin D in health and the nephrotic syndrome. J. Lab. Clin. Med. 99(3): 325–330. PMID:6977006.
74. Shimada, T., Hasegawa, H., Yamazaki, Y., Muto, T., Hino, R., Takeuchi, Y., et al. 2004a. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 19(3): 429–435. doi:10.1359/JBMR.0301264. PMID:15040831.
75. Shimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., et al. 2004b. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 113(4): 561–568. doi:10.1172/JCI200419081. PMID:14966565.
76. Shimada, T., Urakawa, I., Yamazaki, Y., Hasegawa, H., Hino, R., Yoneya, T., et al. 2004c. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem. Biophys. Res. Commun. 314(2): 409–414. doi:10.1016/j.bbrc.2003.12.102. PMID: 14733920.
77. Shimada, T., Yamazaki, Y., Takahashi, M., Hasegawa, H., Urakawa, I., Oshima, T., et al. 2005. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am. J. Physiol. Renal Physiol. 289(5): F1088–F1095. doi:10.1152/ajprenal.00474.2004. PMID:15998839.
78. Shoji, T., Shinohara, K., Kimoto, E., Emoto, M., Tahara, H., Koyama, H., et al. 2004. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol. Dial. Transplant. 19(1): 179–184. doi:10.1093/ndt/gfg513. PMID:14671054.
79. Sitara, D., Razzaque, M.S., Hesse, M., Yoganathan, S., Taguchi, T., Erben, R.G., et al. 2004. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 23(7): 421–432. doi:10.1016/j.matbio.2004.09.007. PMID:15579309.
80. Sitara, D., Razzaque, M.S., St-Arnaud, R., Huang, W., Taguchi, T., Erben, R.G., et al. 2006. Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am. J. Pathol. 169(6): 2161–2170. doi:10.2353/ajpath.2006.060329. PMID:17148678.
81. Sitara, D., Kim, S., Razzaque, M.S., Bergwitz, C., Taguchi, T., Schuler, C., et al. 2008. Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet. 4(8): e1000154. doi:10.1371/journal.pgen.1000154. PMID: 18688277.
82. Tenenhouse, H.S. 1999. X-linked hypophosphataemia: a homologous disorder in humans and mice. Nephrol. Dial. Transplant. 14(2): 333–341. doi:10.1093/ndt/14.2.333. PMID:10069185.
83. Theodoratou, E., Tzoulaki, I., Zgaga, L., and Ioannidis, J.P. 2014. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and metaanalyses of observational studies and randomised trials. BMJ, 348: g2035. doi:10.1136/bmj.g2035. PMID:24690624.
84. Trivedi, D.P., Doll, R., and Khaw, K.T. 2003. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ, 326(7387): 469. doi:10.1136/bmj.326.7387.469. PMID:12609940.
85. Tsujikawa, H., Kurotaki, Y., Fujimori, T., Fukuda, K., and Nabeshima, Y. 2003. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol. Endocrinol. 17(12): 2393–2403. doi:10.1210/me.2003-0048. PMID:14528024.
86. Tukaj, C. 2008. Enhanced proliferation of aortal smooth muscle cells treated by 1,25(OH)2D3 in vitro coincides with impaired formation of elastic fibres. Int. J. Exp. Pathol. 89(2): 117–124. doi:10.1111/j.1365-2613.2008.00578.x. PMID: 18336529.
87. Tukaj, C., Kubasik-Juraniec, J., and Kraszpulski, M. 2000. Morphological changes of aortal smooth muscle cells exposed to calcitriol in culture. Med. Sci. Monit. 6(4): 668–674. PMID:11208389.
88. Vaziri, N.D., Hollander, D., Hung, E.K., Vo, M., and Dadufalza, L. 1983. Impaired intestinal absorption of vitamin D3 in azotemic rats. Am. J. Clin. Nutr. 37(3): 403–406. PMID:6299090.
89. Veldman, C.M., Cantorna, M.T., and DeLuca, H.F. 2000. Expression of 1,25- dihydroxyvitamin D(3) receptor in the immune system. Arch. Biochem. Biophys. 374(2): 334–338. doi:10.1006/abbi.1999.1605. PMID:10666315.
90. Vieth, R. 2006a. Critique of the considerations for establishing the tolerable upper intake level for vitamin D: critical need for revision upwards. J. Nutr. 136(4): 1117–1122. PMID:16549491.
91. Vieth, R. 2006b. What is the optimal vitamin D status for health? Prog. Biophys. Mol. Biol. 92(1): 26–32. doi:10.1016/j.pbiomolbio.2006.02.003. PMID:16766239.
92. Vieth, R. 2012. Implications for 25-hydroxyvitamin D testing of public health policies about the benefits and risks of vitamin D fortification and supplementation. Scand. J. Clin. Lab. Invest. Suppl. 243: 144–153. doi:10.3109/00365513.2012.682893. PMID:22536776.
93. Vieth, R., Chan, P.C., and MacFarlane, G.D. 2001. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am. J. Clin. Nutr. 73(2): 288–294. PMID:11157326.
94. Vieth, R., Bischoff-Ferrari, H., Boucher, B.J., Dawson-Hughes, B., Garland, C.F., Heaney, R.P., et al. 2007. The urgent need to recommend an intake of vitamin D that is effective. Am. J. Clin. Nutr. 85(3): 649–650. PMID:17344484.
95. Voormolen, N., Noordzij, M., Grootendorst, D.C., Beetz, I., Sijpkens, Y.W., van Manen, J.G., et al. 2007. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol. Dial. Transplant. 22(10): 2909–2916. doi:10.1093/ndt/gfm286. PMID:17517792.
96. Wang, T.J., Pencina, M.J., Booth, S.L., Jacques, P.F., Ingelsson, E., Lanier, K., et al. 2008. Vitamin D deficiency and risk of cardiovascular disease. Circulation, 117(4): 503–511. doi:10.1161/CIRCULATIONAHA.107.706127. PMID:18180395.
97. White, K.E., Carn, G., Lorenz-Depiereux, B., Benet-Pages, A., Strom, T.M., and Econs, M.J. 2001. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 60(6): 2079–2086. doi:10.1046/j.1523-1755.2001.00064.x. PMID:11737582.
98. Wolf, M., and Thadhani, R. 2007. Vitamin D in patients with renal failure: a summary of observational mortality studies and steps moving forward. J. Steroid Biochem. Mol. Biol. 103(3–5): 487–490. doi:10.1016/j.jsbmb.2006.11.009. PMID:17197169.